Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: An integrated safety analysis

Journal of Clinical Oncology

Volumn 32, Issue 25, 2014, Pages 2750-2757

  Diéras, Véronique ^a   Harbeck, Nadia ^b   Budd, G Thomas ^c   Greenson, Joel K ^d   Guardino, Alice E ^e   Samant, Meghna ^e   Chernyukhin, Nataliya ^e   Smitt, Melanie C ^e   Krop, Ian E ^f  

^a INSTITUT CURIE   (France)

^b UNIVERSITY OF MUNICH   (Germany)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e GENENTECH INC   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BREAST METASTASIS; CANCER CHEMOTHERAPY; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOTOXICITY; DECREASED APPETITE; DIARRHEA; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; HYPERTENSION; HYPOKALEMIA; MALE; NAUSEA; NODULAR HYPERPLASIA; NODULAR REGENERATIVE HYPERPLASIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; VERY ELDERLY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; ENZYMOLOGY; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAYTANSINE; MIDDLE AGED; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84906819100     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.4999     Document Type: Article

References (19)

1. Genentech: Kadcyla (ado-trastuzumab emtansine) prescribing information. South San Francisco, CA, Genentech, 2013
2. Lewis Phillips GD, Li G, Dugger DL, et al: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280-9290, 2008
3. Lopus M, Oroudjev E, Wilson L, et al: Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9:2689-2699, 2010
4. Junttila TT, Li G, Parsons K, et al: Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356, 2011
5. Krop IE, Beeram M, Modi S, et al: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704, 2010
6. Burris HA 3rd, Rugo HS, Vukelja SJ, et al: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405, 2011
7. Krop IE, LoRusso P, Miller KD, et al: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30: 3234-3241, 2012
8. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
9. Gupta M, Wang B, Carrothers TJ, et al: Effects of trastuzumab emtansine (T-DM1) on QT interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Pharmacol Drug Dev 2:11-24, 2013
10. Hurvitz SA, Dirix L, Kocsis J, et al: Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157-1163, 2013
11. Reshamwala PA, Kleiner DE, Heller T: Nodular regenerative hyperplasia: Not all nodules are created equal. Hepatology 44:7-14, 2006
12. Hartleb M, Gutkowski K, Milkiewicz P: Nodular regenerative hyperplasia: Evolving concepts on underdiagnosed cause of portal hypertension. World J Gastroenterol 17:1400-1409, 2011
13. Wildiers H, Kim S-B, Gonzalez-Martin A, et al: T-DM1 for HER2-positive MBC: primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. Presented at the European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013
14. Mahapatra K, Darbonne WC, Bumbaca D, et al: Trastuzumab emtansine (T-DM1)-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner. Presented at AACR-EORTC-NCI International Conference: Molecular Targets and Cancer Therapeutics, San Francisco, CA, November 12-16, 2011
15. Poon KA, Flagella K, Beyer J, et al: Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 273:298-313, 2013
16. Helft PR, Schilsky RL, Hoke FJ, et al: A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 10: 4363-4368, 2004
17. Issell BF, Crooke ST: Maytansine. Cancer Treat Rev 5:199-207, 1978
18. Cassady JM, Chan KK, Floss HG, et al: Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 52:1-26, 2004
19. Krop IE, Suter TM, Dirix L, et al: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer: Final data from TDM4874g. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2013